Pediatric patient with atopic dermatitis on Dupilumab treatment atopic dermatitis
Conditions
Interventions
Intranasal live influenza vaccine is administered to eligible patients.
live vaccine, Influenza
Sponsors
Nagasawa Koo
Ishiwada Naruhiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following requirements are eligible 1) 2 years of age and older but less than 19 years of age 2) Atopic dermatitis being treated with dupilumab 3) Patients who wish to receive the live influenza vaccine.
Exclusion criteria
Exclusion criteria: Patients with any of the following conditions are not eligible 1) Patients in poor general health 2) Patients with gelatin allergy 3) Pregnant patients 4) Patients who have previously received Flumist 5) Patients on Flumist contraindicated drugs 6) Other than the above, patients deemed by the physician to be inappropriate to participate in the program
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of fourfold or greater increase in antibodies to all three types of vaccine-containing influenza viruses before and after vaccination | — |
Secondary
| Measure | Time frame |
|---|---|
| Influenza incidence in the 25 weeks after vaccination Systemic and local adverse events (including influenza-like symptoms) 4 weeks after vaccination | — |
Contacts
Public ContactKoo Nagasawa
Chiba University Hospital
Outcome results
None listed